Ex-Re­cep­tos CTO co-founds SD start­up Escient, launch­ing with $40M Se­ries A

Af­ter the whop­ping $7.2 bil­lion sale of his last ven­ture, Re­cep­tos, to Cel­gene back in 2015, Mar­cus Boehm wasn’t sup­posed to start an­oth­er com­pa­ny. He was go­ing to take a back­seat, for once. Con­sult. Be on a few boards.

“I’ve been in­volved in three com­pa­nies since found­ing stages, and I was not in­tend­ing to do this again,” Boehm tells me.

Now, he and an­oth­er biotech big shot in San Diego are join­ing forces to launch a rather am­bi­tious start­up, step­ping out Wednes­day with a $40 mil­lion Se­ries A round.

Mar­cus Boehm

You might know Boehm’s name from his time at San Diego’s Re­cep­tos, where he was co-founder and chief tech­nol­o­gy of­fi­cer un­til Cel­gene’s pur­chase. Be­fore that, he was at Con­for­ma un­til it was bought by Bio­gen. Af­ter Re­cep­tos’ sale, Boehm had in­ten­tions of kick­ing back for a while.

But then Alain Baron came along, and he in­tro­duced Boehm to dis­cov­er­ies made by Johns Hop­kins neu­ro­sci­en­tist Xinzhong Dong. To­geth­er, the three of them co-found­ed Escient Phar­ma­ceu­ti­cals, a new San Diego-based com­pa­ny that plans to cre­ate an en­tire­ly new class of drugs.

Boehm said it was this — the al­lure of dis­cov­ery-stage sci­ence — that drew him back in­to the start­up game. If it was a com­pa­ny fur­ther along in de­vel­op­ment, he’d have like­ly passed.

“In many ways, a com­pound will live or die by its prop­er­ties,” Boehm said. “Once it’s in Phase II, there’s not much you can af­fect. If it has tox­i­c­i­ty, for ex­am­ple, there’s not much you can do about it. The dis­cov­ery part is over, and it be­comes a high­ly-or­ches­trat­ed dance of de­vel­op­ment.”

Alain Baron

Boehm serves as Escient’s CSO, while Baron, the founder and for­mer chief ex­ec­u­tive of El­celyx, will head the start­up as CEO.

The com­pa­ny hopes to de­vel­op a pipeline of drugs around a nov­el fam­i­ly of G-pro­tein cou­pled re­cep­tors (GPCRs). GPCRs them­selves are a gi­ant pro­tein fam­i­ly of re­cep­tors that de­tect mol­e­cules out­side the cell and ac­ti­vate cel­lu­lar re­spons­es. If you had to make a wild guess about the tar­get of a cer­tain drug, your best bet is with GPCRs. They make up some­thing like 35% of all drugs on the mar­ket to­day, Baron said.

But Escient has its hands on tech from Dong’s lab on a nov­el fam­i­ly of Mas-re­lat­ed G-pro­tein re­cep­tors, which Baron said have the po­ten­tial to be a com­plete­ly new class of GCPR-tar­get­ed drugs.

“This is not like tak­ing a known tar­get and mak­ing a bet­ter drug or bring­ing an­oth­er med­i­cine to a dis­ease area that’s al­ready well-served,” Baron said. “We’re ac­tu­al­ly go­ing to bring very nov­el ther­a­pies to dis­eases that are un­served — and that’s in­cred­i­bly ex­cit­ing.”

Xinzhong Dong

Baron and Boehme aren’t dis­clos­ing much on their tech, but they did say Escient has nailed down two tar­gets in two in­di­ca­tions. The Se­ries A round — backed by The Col­umn Group, 5AM Ven­tures, and Os­age Uni­ver­si­ty Part­ners — will get the com­pa­ny to the end of 2021. Baron ex­pects the com­pa­ny to be in the clin­ic with one or two pro­grams by then.

In the com­ing months, Escient will be nail­ing down of­fice space for its head­quar­ters in San Diego, hir­ing 15 to 20 peo­ple, and fill­ing out their ex­ec­u­tive team, Baron said.

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

President Trump walks past HHS secretary Alex Azar (Getty Images)

Azar falls in line un­der Trump again. Ex­perts say he's re­in­forc­ing a dark sig­nal sent to the FDA

In the latest incident where Alex Azar has steadfastly taken the side of President Donald Trump over that of the FDA, the HHS secretary was noncommittal this morning when asked if he supports the attempt by his subordinates at the FDA to strengthen guidelines for a vaccine EUA.

Appearing on NBC’s Today Show, the HHS secretary muddied the waters, stating that the guidance that matters is the one that is “actually already out there.”

CDC’s Robert Redfield, NIAID’s Anthony Fauci, Admiral Brett Giroir at HHS, and FDA’s Stephen Hahn prepare to testify at a House hearing on June 23 (Getty)

'Ex­treme­ly po­lit­i­cal' — Trump neuters FDA's at­tempt to strength­en vac­cine EUA

Stephen Hahn went before a Senate committee Wednesday and declared he’s fighting. “Every one of the decisions we have reached has been made by career FDA scientists based on science and data, not politics,” he exclaimed, adding that “FDA will not permit any pressure from anyone to change that. I will fight for science.”

A few hours later, he was undermined by President Donald Trump when a reporter asked if he was okay with stricter vaccine guidelines that the FDA was said to be cooking up. “That has to be approved by the White House. We may or may not approve it. That sounds like a political move,” he decided.

David Berry (Flagship)

Flag­ship's next big tech­no­log­i­cal bet? The cloud

Earlier this month, Flagship announced their big bet on the software half the industry is talking about, launching the AI and machine learning startup. Now, they and a couple other investors are gambling $100 million on a software that much of the public generally thinks of as a cool, IT afterthought: cloud computing.

The idea, says founder and Flagship partner David Berry, is one of scale: The sheer magnitude of biological data that you can store on cloud technology is unprecedented. And that size, when leveraged properly, can allow you to ask questions and form insights that are similarly unprecedented.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust of the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

Patrick Enright, Longitude co-founder (Longitude)

As its biotechs hit the pan­dem­ic ex­it, Lon­gi­tude rais­es $585M for new neu­ro, can­cer, ag­ing and or­phan-fo­cused fund

The years have been kind to Longitude Capital. This year, too.

A 2006 spinout of Pequot Capital, its founders started their new firm just four years before the parent company would go under amid insider trading allegations. Their first life sciences fund raised $325 million amid the financial crisis, they added a second for $385 million and then in, 2016, a third for $525 million. In the last few months, the pandemic biotech IPO boom netted several high-value exits from those funds, as Checkmate, Vaxcyte, Inozyme and Poseida all went public.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

Laura Shawver (Silverback Therapeutics)

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.

The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.

In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”

Covid-19 roundup: Op­er­a­tion Warp Speed's 7th vac­cine is live at­ten­u­at­ed; Small biotech touts big suc­cess where gi­ants have failed

Operation Warp Speed is stacking its vaccine portfolio with a “TBD” new candidate: a live attenuated vaccine that can be administered in a single dose, potentially as an oral formulation rather than an injection.

Sound familiar?

That could be because the unannounced candidate appears to match the profile of an inoculation being developed by Merck, according to Bloomberg, which first reported the development based on a presentation by Moncef Slaoui.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Therapies has become the latest biotech to make a quick ascent from a small, privately-funded company to enjoying its very own Nasdaq ticker.

The Dallas-based biotech raised $157 million for its IPO after pricing shares at $20 apiece Thursday, the high-point of its expected range. Initially pegging $100 million in financing, Taysha offered a little less than 8 million shares and will trade under the $TSHA symbol.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.